Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage i ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 3, 2013, Pages 285-292

  Zacharakis, Dimitrios ^a   Thomakos, Nikolaos ^a   Biliatis, Ioannis ^a   Rodolakis, Alexandros ^a   Simou, Maria ^a   Daskalakis, Georgios ^a   Bamias, Aris ^a   Antsaklis, Aris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Borderline ovarian tumors; CA 125; epithelial ovarian carcinoma; ovarian neoplasms; ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BORDERLINE OVARY TUMOR; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; EPITHELIAL OVARY CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA; CONFIDENCE INTERVALS; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, COLOR; YOUNG ADULT;

EID: 84874424343     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12046     Document Type: Article

References (25)

1. Taylor HC,. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet. 1929; 48: 204-30.
2. Gershenson DM,. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol. 2002; 16: 513-27.
3. Cadron I, Amant F, Van GT, Neven P, Leunen K, Vergote I,. The management of borderline tumours of the ovary. Curr Opin Oncol. 2006; 18: 488-93.
4. Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004; 35: 910-7.
5. Hidlebaugh DA, Vulgaropulos S, Orr RK,. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med. 1997; 42: 551-8.
6. Valentin L, Jurkovic D, Van CB, Testa A, Van HC, Bourne T, et al. Adding a single CA-125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol. 2009; 34: 345-54.
7. Tamakoshi K, Kikkawa F, Shibata K, Tomoda K, Obata NH, Wakahara F, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol. 1996; 62: 67-72.
8. Lee EJ, Kim SH, Kim YH, Lee HJ,. Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma? Acta Radiol. 2011; 52: 458-62.
9. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2005; 25: 50-9.
10. Valentin L, Ameye L, Testa A, Lecuru F, Bernard JP, Paladini D, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol. 2006; 102: 41-8.
11. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I,. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000; 16: 500-5.
12. International Federation of Gynaecology and Obstetrics. Annual report and results of treatment in gynaecologic cancer. Int J Gynaecol Obstet. 1989; 28: 189-90.
13. Pascual MA, Tresserra F, Grases PJ, Labastida R, Dexeus S,. Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound. 2002; 30: 76-82.
14. Kennedy AW, Hart WR,. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer. 1996; 78: 278-86.
15. Bent CL, Sahdev A, Rockall AG, Singh N, Sohaib SA, Reznek RH,. MRI appearances of borderline ovarian tumours. Clin Radiol. 2009; 64: 430-8.
16. deSouza NM, O'Neill R, McIndoe GA, Dina R, Soutter WP,. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. Am J Roentgenol. 2005; 184: 999-1003.
17. Timmerman D, Bourne TH, Tailor A, Collins WP, Verrelst H, Vandenberghe K, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol. 1999; 181: 57-65.
18. Van CB, Timmerman D, Bourne T, Testa AC, Van HC, Domali E, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst. 2007; 99: 1706-14.
19. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG,. A risk of malignancy index incorporating CA-125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990; 97: 922-9.
20. Tingulstad S, Hagen B, Skjeldestad FE, OnsrudM, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996; 103: 826-31.
21. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M,. The Risk of Malignancy Index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999; 93: 448-52.
22. Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T,. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol. 2009; 144: 163-7.
23. Håkansson F, Høgdall EV, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, et al. Risk of malignancy index used as a diagnostic tool in a tertiary center for patients with a pelvic mass. Acta Obstet Gynecol Scand. 2012; 91: 496-502.
24. Van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, et al. Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. Gynecol Oncol. 2010; 116: 384-8.
25. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010; 29: 203-11.